Yestar Healthcare Holdings Company Limited (stock code: 02393, “Yestar Health”) has released additional details on its previously announced acquisitions of production equipment for advanced materials.

Key points:

1. Consideration in line with market value • Independent valuer Beijing Yingyue Asset Appraisal Co., Ltd. assessed the production and main equipment at approximately RMB55.88 million (US$7.87 million) as of 15 October 2025. • The valuer adopted the cost approach after ruling out the market and income approaches due to limited secondary-market data and high earnings uncertainty at the asset-acquisition stage. • Replacement cost was determined using recent FOB purchase prices, plus freight, insurance, handling, installation and financing expenses, and adjusted solely for physical depreciation (assets are brand-new).

2. Valuation assumptions and validity Key assumptions include stable macroeconomic conditions, unchanged regulatory and tax regimes, and availability of required licences. The valuation is valid for one year—from 15 October 2025 to 14 October 2026—after which an updated appraisal will be required.

3. Delivery schedule deemed reasonable Both the production and main equipment are to be delivered within four months of payment. The Board cites the equipment’s bulk and complexity, required disassembly, and Dutch export-licence procedures as justifying the timetable. Yestar Health will continue to track licence approval and logistics with the vendor to ensure timely delivery.

4. Vendor information The equipment is being supplied by a vendor ultimately owned by Mr. Ho Tony, whom the Board confirms is an independent third party.

Board conclusion Based on the independent valuation and confirmed delivery plan, the Board considers the agreed consideration fair, on normal commercial terms and in the best interests of the company and its shareholders.